Literature DB >> 27175839

Glaucoma.

Divakar Gupta1, Philip P Chen2.   

Abstract

Glaucoma is a set of irreversible, progressive optic neuropathies that can lead to severe visual field loss and blindness. The two most common forms of glaucoma, primary open-angle glaucoma and primary angle-closure glaucoma, affect more than 2 million Americans and are increasing in prevalence. Many patients with glaucoma are asymptomatic and do not know they have the disease. Risk factors for primary open-angle glaucoma include older age, black race, Hispanic origin, family history of glaucoma, and diabetes mellitus. Risk factors for primary angle-closure glaucoma include older age, Asian descent, and female sex. Advanced disease at initial presentation and treatment nonadherence put patients with glaucoma at risk of disease progression to blindness. The U.S. Preventive Services Task Force has concluded that the evidence is insufficient to assess the potential benefits and harms of screening for glaucoma in the primary care setting. Regular eye examinations for adults are recommended by the American Academy of Ophthalmology, with the interval depending on patient age and risk factors. Diagnosis of glaucoma requires careful optic nerve evaluation and functional studies assessing a patient's visual field. The goal of treatment with eye drops, laser therapy, or surgery is to slow visual field loss by lowering intraocular pressure. Family physicians can contribute to lowering morbidity from glaucoma through early identification of high-risk patients and by emphasizing treatment adherence in patients with glaucoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27175839

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  32 in total

1.  Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients.

Authors:  Palwasha Mokhles; Luuk van Gorcom; Jan S A G Schouten; Tos T J M Berendschot; Henny J M Beckers; Carroll A B Webers
Journal:  Eye (Lond)       Date:  2020-06-03       Impact factor: 3.775

2.  Paying attention to the intraocular pressure in the early postoperative phase after Ahmed glaucoma valve surgery in Black or Hispanics.

Authors:  Christoph Faschinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-19       Impact factor: 3.535

3.  Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma.

Authors:  Mariaelena Filippelli; Giuseppe Campagna; Nicola Ciampa; Gaetano Fioretto; Roberta Giannini; Pier Franco Marino; Roberto dell'Omo; Ciro Costagliola
Journal:  J Clin Med       Date:  2022-06-19       Impact factor: 4.964

4.  A comprehensive map of disease networks and molecular drug discoveries for glaucoma.

Authors:  Haixin Wang; Yanhui Deng; Ling Wan; Lulin Huang
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

5.  The Frequency and Causes of Blindness in a Rural Region of Central Anatolia of Turkey.

Authors:  Enver Mirza; Gunsu Deniz Mirza; Refik Oltulu; Mehmet Okka; Ahmet Ozkagnici
Journal:  Eurasian J Med       Date:  2019-10

Review 6.  Myeloid cells in retinal and brain degeneration.

Authors:  Michelle Guo; Turner D Schwartz; Joshua L Dunaief; Qi N Cui
Journal:  FEBS J       Date:  2021-09-15       Impact factor: 5.622

7.  Down-regulated LAMA4 inhibits oxidative stress-induced apoptosis of retinal ganglion cells through the MAPK signaling pathway in rats with glaucoma.

Authors:  Chong Wang; Ya-Lin Ren; Jin Zhai; Xiao-Yan Zhou; Jing Wu
Journal:  Cell Cycle       Date:  2019-04-19       Impact factor: 5.173

Review 8.  Diet, Oxidative Stress, and Blood Serum Nutrients in Various Types of Glaucoma: A Systematic Review.

Authors:  Maryla Młynarczyk; Martyna Falkowska; Zuzanna Micun; Iwona Obuchowska; Jan Kochanowicz; Katarzyna Socha; Joanna Konopińska
Journal:  Nutrients       Date:  2022-03-29       Impact factor: 5.717

9.  Preservation of optic nerve structure by complement inhibition in experimental glaucoma.

Authors:  Caroline J Gassel; Sabrina Reinehr; Sara C Gomes; H Burkhard Dick; Stephanie C Joachim
Journal:  Cell Tissue Res       Date:  2020-07-17       Impact factor: 5.249

10.  Predicting Adherence With the Glaucoma Treatment Compliance Assessment Tool.

Authors:  Facundo G Sanchez; Steven L Mansberger; Paula A Newman-Casey
Journal:  J Glaucoma       Date:  2020-11       Impact factor: 2.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.